Fresenius Medical Care AG (NYSE:FMS - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $23.17, but opened at $24.22. Fresenius Medical Care shares last traded at $24.23, with a volume of 53,280 shares.
Analyst Upgrades and Downgrades
Several research analysts have commented on the stock. Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. StockNews.com began coverage on Fresenius Medical Care in a research note on Friday, January 3rd. They set a "strong-buy" rating for the company. Truist Financial upped their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Finally, Berenberg Bank started coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a "buy" rating and a $25.60 price target for the company.
Read Our Latest Report on FMS
Fresenius Medical Care Stock Performance
The company's 50-day moving average price is $22.87 and its two-hundred day moving average price is $21.00. The stock has a market cap of $14.45 billion, a PE ratio of 20.35, a PEG ratio of 0.75 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.
Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.03. The firm had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.36 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. During the same quarter in the previous year, the company posted $0.31 earnings per share. On average, equities research analysts forecast that Fresenius Medical Care AG will post 1.53 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the business. DAVENPORT & Co LLC grew its stake in shares of Fresenius Medical Care by 1.5% during the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company's stock valued at $1,316,000 after buying an additional 862 shares during the last quarter. Blue Trust Inc. boosted its holdings in Fresenius Medical Care by 15.6% during the 4th quarter. Blue Trust Inc. now owns 14,876 shares of the company's stock valued at $317,000 after acquiring an additional 2,013 shares during the period. Crossmark Global Holdings Inc. grew its position in Fresenius Medical Care by 2.2% during the 4th quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company's stock worth $1,456,000 after acquiring an additional 1,398 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new position in Fresenius Medical Care in the 4th quarter worth approximately $201,000. Finally, GAMMA Investing LLC lifted its position in Fresenius Medical Care by 43.3% in the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company's stock valued at $162,000 after purchasing an additional 2,166 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors.
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
